{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:12:28Z","timestamp":1763017948335,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Merit Review Award","award":["I01BX001923","I01BX000398"],"award-info":[{"award-number":["I01BX001923","I01BX000398"]}]},{"name":"Senior Research Career Scientist","award":["IK6B004200"],"award-info":[{"award-number":["IK6B004200"]}]},{"name":"United States (US) Department of Veterans Affairs"},{"name":"Biomedical Laboratory Research Development Program"},{"name":"Artery Therapeutics, Inc. and Swedish Research Council","award":["K2014-54XX-22426-0-"],"award-info":[{"award-number":["K2014-54XX-22426-0-"]}]},{"DOI":"10.13039\/501100001858","name":"Swedish Governmental Agency for Innovation Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.mce.2018.09.011","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T01:56:58Z","timestamp":1538445418000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Novel ABCA1 peptide agonists with antidiabetic action"],"prefix":"10.1016","volume":"480","author":[{"given":"Salman","family":"Azhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5150-1698","authenticated-orcid":false,"given":"Wen-Jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4313-2666","authenticated-orcid":false,"given":"Jens O.","family":"Lagerstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-7807","authenticated-orcid":false,"given":"Fredric B.","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan O.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2018.09.011_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"ACCORD Study Group","year":"2011","journal-title":"N Eng J Med"},{"key":"10.1016\/j.mce.2018.09.011_bib2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2018.09.011_bib3","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.mce.2018.09.011_bib4","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.2337\/dc15-S011","article-title":"Cardiovascular disease and risk management. Sec. 8. In standards of medical Care in Diabetes\u20142015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.mce.2018.09.011_bib5","doi-asserted-by":"crossref","first-page":"E1323","DOI":"10.1152\/ajpendo.90617.2008","article-title":"Evaluating the glucose tolerance test in mice","volume":"295","author":"Andrikopoulos","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2018.09.011_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like-peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.mce.2018.09.011_bib7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1194\/jlr.M003665","article-title":"A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice","volume":"51","author":"Bielicki","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.mce.2018.09.011_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1478-7954-8-29","article-title":"Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality and prediabetes prevalence","volume":"8","author":"Boyle","year":"2010","journal-title":"Popul Health Metr"},{"year":"2017","series-title":"National Diabetes Statistics Report, 2017: Estimates of Diabetes and its Burden in the United States","author":"Centers for Disease Control and Prevention (CDC)","key":"10.1016\/j.mce.2018.09.011_bib9"},{"key":"10.1016\/j.mce.2018.09.011_bib10","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev-physiol-021113-170315","article-title":"Glucagon-like peptide-1: glucose homeostasis and beyond","volume":"76","author":"Cho","year":"2014","journal-title":"Ann Rev Physiol"},{"key":"10.1016\/j.mce.2018.09.011_bib12","first-page":"1132","volume":"vol. 100","author":"Circulation","year":"1999"},{"key":"10.1016\/j.mce.2018.09.011_bib13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease in the collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomized placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2018.09.011_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1194\/jlr.M032904","article-title":"Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle","author":"Dalla-Riva","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.mce.2018.09.011_bib15","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2337\/db15-1493","article-title":"Dual actions apolipoprotein A-I on glucose-stimulated insulin secretion and insulin-independent peripheral tissue glucose uptake lead to increased heart and skeletal muscle glucose disposal","volume":"65","author":"Domingo-Espin","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2018.09.011_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mce.2018.09.011_bib17","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1056\/NEJMsa053935","article-title":"Explaining the decrease in the U.S. deaths from coronary disease, 1980-2000","volume":"356","author":"Ford","year":"2007","journal-title":"N Eng J Med"},{"key":"10.1016\/j.mce.2018.09.011_bib18","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.292.20.2495","article-title":"Trends in cardiovascular complications of diabetes","volume":"292","author":"Fox","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.mce.2018.09.011_bib19","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1161\/CIRCULATIONAHA.106.658948","article-title":"Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham heart","volume":"115","author":"Fox","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2018.09.011_bib20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Eng J Med"},{"key":"10.1016\/j.mce.2018.09.011_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIR.0b013e318282ab8f","article-title":"Executive summary: heart disease and stroke statistics\u20142013 update: a report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2018.09.011_bib22","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of metformin on cardiovascular disease: a meta-analysis of randomized trials among people with type 2 diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.mce.2018.09.011_bib23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/01.CIR.100.10.1134","article-title":"Diabetes and Cradiovascular disease: a Statement for Healthcare Professionals from the American heart association","volume":"100","author":"Grundy","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2018.09.011_bib24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.281.14.1291","article-title":"Diabetes and decline in heart disease mortality in US adults","volume":"281","author":"Gu","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.mce.2018.09.011_bib26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.49.3.424","article-title":"Isolation of INS-1-derivedcell lines with robust ATP-sensitive K+ channel-dependent ad \u2013independent glucose-stimulated insulin secretion","volume":"49","author":"Hohmeier","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2018.09.011_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13300-012-0003-x","article-title":"A Review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes","volume":"3","author":"Htike","year":"2012","journal-title":"Diabetes Ther"},{"year":"2017","series-title":"IDF Diabetes Atlas \u2500","author":"International Diabetes Federation","key":"10.1016\/j.mce.2018.09.011_bib28"},{"key":"10.1016\/j.mce.2018.09.011_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"ACCORD trial group","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2018.09.011_bib30","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beem.2016.05.003","article-title":"Type 2 diabetes: a 21st century epidemic","volume":"30","author":"Jaacks","year":"2016","journal-title":"Best Pract Res Clin Endocrinol"},{"key":"10.1016\/j.mce.2018.09.011_bib32","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1016\/S0021-9258(19)85269-9","article-title":"Direct demonstration of insulin-induced GLUT4 translocation to the surface of intact cells by insertion of c-Myc epitope into an exofacial GLUT 4 domain","volume":"268","author":"Kanai","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2018.09.011_bib33","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.2337\/diab.46.6.1087","article-title":"Leptin suppression of insulin secretion by activation of ATP-sensitive K+ channels in pancreatic beta-cells","volume":"46","author":"Kieffer","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2018.09.011_bib34","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1172\/JCI119818","article-title":"Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice","volume":"100","author":"Kulkarni","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mce.2018.09.011_bib35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ehjcvp\/pvv035","article-title":"Cardiovascular safety of anti-diabetic drugs","volume":"2","author":"Kumar","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.mce.2018.09.011_bib37","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2011.04.008","article-title":"Effects of leptin and adiponectin on pancreatic \u03b2-cell function","volume":"60","author":"Lee","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.mce.2018.09.011_bib38","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","article-title":"Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research","volume":"6","author":"Leon","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.mce.2018.09.011_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/DMSO.S130834","article-title":"Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research","volume":"10","author":"Levin","year":"2017","journal-title":"Diabetes Metab Syndrome obes"},{"key":"10.1016\/j.mce.2018.09.011_bib40","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1161\/01.CIR.0000142857.79401.69","article-title":"Differential effects of apolipoprotein AI-mimetic peptide on evolving and established atherosclerosis","volume":"110","author":"Li","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.mce.2018.09.011_bib42","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2796.1997.tb00006.x","article-title":"Diabetes as a risk factor for myocardial infarction: population and gender perspective","volume":"241","author":"Lundberg","year":"1997","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.mce.2018.09.011_bib43","unstructured":"MAYO CLINIC, n.d. Hemoglobin A1c, Blood. Mayo Medical Laboratories. https:\/\/www.mayomedicallaboratories.com\/test-catalog\/Clinical+and+Interpretive\/82080."},{"key":"10.1016\/j.mce.2018.09.011_bib44","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.amjcard.2010.08.009","article-title":"Gender-specific short and long-term mortality in diabetic versus nondiabetic patients with incident acute myocardial infarction in the reperfusion era (the MONICA\/KORA Myocardial Infarction Registry","volume":"106","author":"Meisinger","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.mce.2018.09.011_bib46","first-page":"2","article-title":"Vascular protective effects of diabetes medications that mimic or increase glucagon-like peptide-1 activity. Recent Pat Cardiovasc","volume":"7","author":"Motta","year":"2012","journal-title":"Drug Discov"},{"key":"10.1016\/j.mce.2018.09.011_bib47","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-013-3028-4","article-title":"Exendin-4 protects pancreatic beta cells from palmitate-induced apoptosis by interfering with GPR40 and MKK4\/7 stress kinase signaling pathway","volume":"56","author":"Natalicchio","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.mce.2018.09.011_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.regpep.2004.07.014","article-title":"Glucagon-like peptide 1 and its derivatives in the treatment of diabetes","volume":"128","author":"Nauck","year":"2005","journal-title":"Regul. Pept."},{"key":"10.1016\/j.mce.2018.09.011_bib52","first-page":"3510","article-title":"Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes","volume":"36","author":"Neugebauer","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2018.09.011_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nelson","year":"2004","journal-title":"Regul. Pept."},{"key":"10.1016\/j.mce.2018.09.011_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/bbrc.1997.7274","article-title":"Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets","volume":"238","author":"Pallet","year":"1997","journal-title":"Bibochim. Biophys Res. Commun."},{"key":"10.1016\/j.mce.2018.09.011_bib55","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1194\/jlr.M800046-JLR200","article-title":"L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice","volume":"49","author":"Peterson","year":"2008","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.mce.2018.09.011_bib56","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1194\/jlr.M800610-JLR200","article-title":"The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice","volume":"50","author":"Peterson","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.mce.2018.09.011_bib57","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1210\/endo.139.3.5812","article-title":"Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans","volume":"139","author":"Poitout","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2018.09.011_bib63","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1073\/pnas.96.2.674","article-title":"Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob\/ob mice","volume":"96","author":"Seufert","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.mce.2018.09.011_bib64","first-page":"674","article-title":"Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus","volume":"84","author":"Seufert","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2018.09.011_bib65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mam.2015.09.003","article-title":"Molecular pathophysiology of hepatic glucose production","volume":"46","author":"Sharabi","year":"2015","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.mce.2018.09.011_bib66","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00125-014-3162-7","article-title":"Single injection of apoA-I acutely improves in vivo glucose tolerance in insulin-resistant mice","volume":"57","author":"Stenkula","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.mce.2018.09.011_bib67","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1210\/endo.138.10.5576","article-title":"Direct stimulation of basal insulin secretion by physiological concentrations of leptin in pancreatic beta cells","volume":"138","author":"Tanizawa","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.mce.2018.09.011_bib68","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1159\/000374027","article-title":"Exendin-4 promotes beta cell proliferation via PI3K\/Akt signaling pathway","volume":"35","author":"Wang","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.mce.2018.09.011_bib69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-61779-430-8_27","article-title":"A mouse model of diet-induced obesity and insulin resistance","volume":"821","author":"Wang","year":"2012","journal-title":"Methods Mol. Biol."},{"author":"World Health Organization (WHO)","key":"10.1016\/j.mce.2018.09.011_bib70"},{"key":"10.1016\/j.mce.2018.09.011_bib71","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diabetes.48.5.1026","article-title":"Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob\/ob, db\/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)","volume":"48","author":"Young","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.mce.2018.09.011_bib72","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrendo.2016.105","article-title":"Diabetes mellitus statistics on prevalence and mortality: facts and fallacies","volume":"12","author":"Zimmet","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.mce.2018.09.011_bib73","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Eng J Med"}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720718302818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720718302818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:07:14Z","timestamp":1759586834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720718302818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":59,"alternative-id":["S0303720718302818"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2018.09.011","relation":{},"ISSN":["0303-7207"],"issn-type":[{"type":"print","value":"0303-7207"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel ABCA1 peptide agonists with antidiabetic action","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2018.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}